Pfizer’s stake in ViiV Healthcare will be taken over by Shiongi, another minority shareholder in the HIV medicines company. GSK remains remain the majority shareholder in ViiV, which the pharmaceutical giant formed in partnership with Pfizer in 2009.
Rapt Therapeutics brings to GSK ozureprubart, a long-acting antibody that inhibits the validated immunology target immunoglobulin E (IgE). If GSK is able to bring this drug to the market, it would complete with the blockbuster Genentech and Novartis allergy drug Xolair.
Alan Murray on improving access for medical transportation.
GSK’s bepirovirsen met the main goal of two Phase 3 studies, achieving functional cure rates for patients with chronic hepatitis B infection after six months of treatment. This antisense oligonucleotide therapy could provide a treatment alternative to antiviral drugs that patients must take for life.
GSK’s Exdensur requires just two injections a year to treat severe asthma. Less frequent injections give this new biologic medicine a dosing edge over one of GSK’s own blockbuster respiratory products as well as severe asthma drugs from companies such as AstraZeneca, Sanofi, and Amgen.
GSK submitted the same Blenrep clinical trial data to global regulators and the FDA, but received a slightly more limited regulatory approval in the U.S. In an interview during the annual meeting of the American Society of Hematology, GSK oncology executive Hesham Abdullah explained what else the FDA wants from Blenrep clinical trials.
GSK paid $85 million up front for global rights to a small-interfering RNA therapy discovered and developed by startup Empirico. The pharmaceutical giant said this drug candidate could be used as a monotherapy and as part of drug combinations for treating COPD and other inflammatory respiratory diseases.
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
GSK drug Blenrep, which exited the market in 2022 after failing a confirmatory study, now has a new FDA approval as a third-line multiple myeloma treatment. The U.S. regulatory decision is more limited than the recent European approval for the blood cancer drug.
President Trump has been pursuing policies intended to entice drugmakers to bring manufacturing and jobs to the U.S. GSK’s announcement makes it the latest big pharma company to unveil a multi-billion dollar plan for new U.S. facilities.
The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition.
GSK drug Nucala has expanded its FDA-approved uses to include maintenance treatment of chronic obstructive pulmonary disease that’s driven by eosinophils, a type of immune cell. The antibody drug will compete against the blockbuster Sanofi product Dupixent, which expanded its FDA approval to COPD last year.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
GSK is acquiring Boston Pharmaceuticals’ efimosfermin, which posted Phase 2 results showing improvement in fibrosis and resolution of MASH. GSK said this fusion protein will complement an siRNA drug it is currently developing for liver diseases.
Solu Therapeutics’ platform technology, which was licensed from GSK, pairs a small molecule with an antibody to address elusive disease targets. Cancer is Solu’s initial focus, but the startup is also exploring applications of its platform to immunology.
GSK is licensing an ABL Bio technology that yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease.
The FDA approved GSK antibiotic Blujepa as a treatment for uncomplicated urinary tract infections. The drug’s novel mechanism of action addresses a broader range of pathogens and could offer a way to lower the potential for drug resistance.
Infectious disease is the focus of the biopharma track at INVEST Pitch Perfect May 20-21 in Chicago. Register today!